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PROTEIN CRYSTAL GROWTH RESULTS FROM SHUTTLE FLIGHT 51-F
We have now completed the initial analysis of the PCG experiments that were run on
51-F.
Experimental Procedures
(1) We flew the same general hand-held unit that had been flown on 51-D. Several
major modifications had heen made in the hardware:
(a) We added plungers to close the sample syringes during launch and landing,
since we had lost samples from our syringes at those two stages on 5 1-D.
(b) We replaced the plastic syringe tips with ones made of glass. Most of the
experiments involved cylindrical glass tips with blunt ends, and these tips
were tested on a KC-135 flight.
(c) We included six glass syringe tips that were bell-shaped; the protein
solutions were held within the bells during flight.
(d) Four of the protein drops were tethered during flight, by using the opposing
plungers as tether points.
(e) Teflon tape was placed around eight of the glass syringe tips, to determine
if this hydrophobic barrier would enhance drop stability.
(2) We flew four different proteins on 51-F: lysozyme, <*Z interferon, bacterial
purine nucleoside phosphorylase (PNP), and human C-reactive protein (CRP).
These four proteins were selected because:
(a) We have considerable experience crystallizing these particular proteins at
U.A.B..
(b) They permitted us to assess drop stability for solutions that contained
different types of precipitating agents. Bacterial PNP is crystallized
from ammonium sulfate salt solutions; C-reactive protein is
crystallized from methyl pent anediol; lysozyme is crystallized from
NaCl solutions; and Cf2 interferon is crystallized from polyethylene
glycol. Lysozyme usually crystallizes easily, so it serves as a useful
control. The other three proteins generally crystallize within two
days, but crystals of these proteins obtained in our laboratory at
U.A.B. are small, and diffract only to moderate resolutions.
(3) The PCG experiments on 51-F were performed by Drs. Loren Acton and
Story Musgrave. Larry DeLucas and I met with these two crew members
for about two hours prior to 51-F, to instruct them on the experimental
procedures that were involved.
(4) Our experiments included a dialysis block, and two individual syringe
assemblies. Loren Acton assumed responsibility for activating the dialysis
experiment, and for activating and later deactivating one of the syringe
assemblies. Story Musgrave assumed responsibility for activating and
deactivating the second syringe assembly.
(5) The dialysis unit contained six different dialysis cells. Lysozyme was the
protein that was used for all of these dialysis experiments. The two
individual chambers in the dialysis unit contained different concentrations
of sodium chloride, and each chamber contained three of the dialysis cells.
(6) Each of the two syringe assemblies contained seventeen chambers. All of
the experiments within these chambers were of the vapor diffusion type.
The reservoir solutions for these experiments were held by the same cotton
wictong material that was used on 51-D. However, unlike 51-D, the
reservoir solutions were added to the wicks prior to launch and were
separated from the protein syringes by a metal grid.
(7) Loren Acton began activating the dialysis experiments and one of the
syringe systems one hour and 25 minutes into the mission. This unit was
activated as early as possible, so that we could assess the effects of OMS
burns on drop stability. The syringes were activated by Dr. Acton holding
the assembly on his lap while he was strapped in a flight seat.
(8) The second syringe system was activated by Story Musgrave thirty-six
hours into the mission. These syringes were activated while the syringe
assembly was mounted securely above a light box. Most of the OMS burns
had been completed before this second unit was activated, but at least one
major OMS burn occurred after the unit was activated.
(9) The syringe units were deactivated during the seventh day of the mission.
(10) Photographs were taken of the syringe units after activation and before
deactivation. Unfortunately, these photographs did not show much detail,
since each frame depicts a complete syringe assembly (17 syringes).
(11) The protein sample volumes ranged from 25 Vis to 80 pis for the syringe
experiments, and 50 yls of protein solution was included in each of the
dialysis cells. The reservoirs for the vapor diffusion experiments contained
500-650 Uls. The dialysis chambers each contained about 35 mis of salt
solution.
(12) Larry DeLucas retrieved the hardware in California. The hardware was
delivered to Dr. DeLucas within two hours after the shuttle landing. He
immediately photographed each chamber and recorded any significant
observations while viewing the chambers through a microscope. He arrived
back in Birmingham approximately 8 hours after receiving the hardware in
California, and proceeded with analysis of the samples at U.A.B.
(13) Information concerning the course of the experiments aboard the shuttle
were obtained from dictated notes by Loren Acton and Story Musgrave, and
by later personal interviews with these two crew members.
Experimental Results
(1) Activation of experiments by Loren Acton:
(a) Dialysis experiments were successfully activated less than 2 hours into the
flight.
(b) The three bell-shaped tips in Dr. Acton's syringe assembly were
successfully filled with solution.
(c) The two tethered droplets were successfully formed and stabilized.
(d) Four droplets were lost during deployment. None of these droplets were on
the four syringe tips that contained teflon tape.
(2) Activation of experiments by Story Musgrave:
(a) The plungers on the three bell-shaped syringe tips were extruded beyond
the mouth of the bell, and the protein samples ran behind the plunger back
into the syringe barrels.
(b) Three of the glass syringe tips rotated with the plungers, so the drops could
not be extruded. Two of these rotating syringe tips were among the four
tips in the apparatus that were covered with teflon tape.
(c) The two tethered drops were successfully deployed and joined with the
tethering plunger.
(d) The remaining nine droplets were successfully deployed.
(3) Three droplets were lost from Loren Acton's syringe assembly during flight. It is
not known if these drops were lost during OMS burns, or were lost for other
reasons.
(4) One droplet was lost from Story Musgrave's syringe assembly during flight. He
observed the apparatus after a major OMS burn, and all drops were still intact.
(5) Upon deactivating his syringe assembly, Dr. Acton observed crystals in all three
of the bell tips, and crystals that were attached to the tips of all seven syringes
that retained droplets during flight. According to our instructions, those syringe
tips that had attached crystals after the drops were withdrawn were not sealed
by the closing plungers prior to re-entry. Those protein crystals that had been
observed by Dr. Acton included CRP, lysozyme, interferon and bacterial PNP.
Three of the samples that were lost during flight were fTom syringe tips that
contained teflon tape.
(6) Story Musgrave observed no crystals in his syringe assembly.
(7) When Dr. DeLucas recovered the hardware at the landing site in California, he
noticed that the syringe chambers contained considerable condensation,
suggesting that the apparatus had been through a significant temperature
fluctuation. Mr. Bill Paton, the NASA employee who recovered the hardware
from the shuttle, noted that the temperature in the NASA van had reached 90°F
due to the extreme heat on the runway.
(8) Three of the six dialysis cells had been ruptured, apparently during the activation
process. The three surviving cells contained large tetragonal crystals of
lysozyme with average dimensions of 1.3 x 0.65 x 0.65 mm.
(9) When the hardware was examined at U.A.B., no crystals were observed attached
to the tips of the syringes.
(10) Loren Acton's syringe assembly contained crystals in four of the protein
solutions, but all of these crystals were small and were of poor quality. The
crystals that were observed at U.A.B. in the solutions from the syringes included
lysozyme, interferon, and bacterial PNP. No crystals of CRP were observed.
(11) Story Musgrave's unit had four syringes that contained crystals when analyzed at
U.A.B. These crystals were also small and of poor quality. The crystals from
Dr. Musgrave's unit included interferon, lysozyme and bacterial PNP.
(12) No samples were lost from the syringes upon landing. Four of the syringes in Dr.
Acton's assembly had not been closed with plungers prior to landing, since he had
observed crystals growing off the tips of the syringes. All four of these samples
remained in the syringes during landing, and seemed to have the expected volume
of solution when measured at U.A.B.
(13) The volumes of the protein solutions in Dr. Acton's syringe assembly indicated
that these solutions had reached equilibrium with the reservoirs in the syringe
chambers. At equilibrium, the volume of the protein droplets would have been
decreased by 50%, which was consistent with the final volumes observed in these
syringes.
(14) All of the protein solutions from Dr. Musgrave's syringe assembly contained
larger volumes than would be expected if these protein solutions had reached
equilibrium with the reservoir solutions. Overall, the volumes of the protein
solutions in these assemblies had only decreased by 30-40%.
Summary and Conclusions
(1) Sample stability was much increased over that observed during the experiments
on flight 51-D. Only four droplets were lost during deployment, and these were
all lost by Dr. Acton during a period when he was not feeling well, and was trying
to activate the syringes while holding the assembly on his lap. Only four droplets
were lost during flight, despite an unusually large number of OMS burns. Both
Dr. Acton and Dr. Musgrave felt that the current syringe systems are adequate
for stabilizing the droplets, if the unit is properly anchored during activation,
deactivation and photography.
(2) The dialysis experiments produced lysozyme crystals that were significantly
larger than those obtained in our identical ground-based studies, using the flight
hardware and procedures. The lysozyme crystals that we obtained during the
ground-based studies were all less than 0.7 mm in the longest dimension, whereas
the flight crystals had average dimensions of 1.3 x 0.65 x 0.65 mm.
(3) Temperature fluctuations apparently caused problems during the crystallization
experiments on 51-F. The condensation observed in the chambers upon retrieval
of the hardware in California indicated that the samples had reached an elevated
temperature and then had cooled back to room temperature. The information
that we have suggests that this temperature rise took place after the shuttle
landed. Presumably, the crystals that were observed by Dr. Acton may have
been destroyed by this rise in temperature.
(4) Our ground-based studies indicated that teflon tape would stabilize droplets on
these syringe tips. The teflon tape did seem to assist in drop stability during
deployment. However, three drops were lost from taped tips during flight.
(5) It is interesting that samples survived during the re-entry and landing in glass
tips that were not stoppered with plungers. We had lost nearly all of the liquid
from syringes on shuttle flight 51-D, but we had used polypropylene syringes on
that flight. It is possible that the glass syringe tips hold the liquids more tightly
by capillary action, and it is possible that some future experiments can be run
without the necessity of using a plunger to close the tips of the syringes on
launch and landing.
(6) It is clear that the protein samples had not completely equilibrated with the
reservoirs in Dr. Musgrave's syringe assembly, whereas equilibration appears to
have been completed in Dr. Acton's assembly. Dr. Musgrave's experiments were
activated some 34 hours after those that were initiated by Dr. Acton, so the
time for equilibration was somewhat different. From the ground-based studies,
we had expected that equilibration should be complete within 2-4 days for all of
these vapor-diffusion experiments. Thus it appears that the vapor diffusion rates
are somewhat slower under microgravity conditions.
(7) Drop tethering was highly successful. All four of the tethered drops were stable,
even though they contained MPD solutions.
(8) The main purpose of the PCG experiments on 51-F was to assess the hardware
and experimental procedures that are being developed for future flights, when
temperature control will be available. However, we also obtained some
encouraging results with lysozyme crystal growth. Using micro-dialysis methods,
we obtained lysozyme crystals that are considerably larger than ones obtained on
the ground, using the identical apparatus and procedures.
Plans for Future Experiments
(1) We are encouraged by the results relating to drop stability on these blunt-end,
siliconized glass tips. We feel that teflon coatings around the outside of the tips
further enhances drop stability, and we are now investigating shrink wrapped
teflon sleeves for further stabilizing the drops. We are also considering using
drops with average volumes that are less that the 80 yl drops that were flown on
51-F, in order to enhance drop stability and accelerate equilibration rates.
(2) We are now running ground-based experiments designed to optimize the
equilibration rates in our vapor-diffusion chambers. There are three possible
changes that are now being tested:
(a) We are experimenting with methods for maximizing the surface area of
wicking material by running wick around the chamber walls. Our initial
" -50% by
increasing the wicking surface area, and by bringing the wicking materials
closer to the protein droplets.
(b) We are examining alternatives to the metal grid that we have been using to
separate the equilibration reservoir from the protein samples. Our current
grid decreases the available surface area considerably, and we are
experimenting with other mechanisms for restraining the wicking material.
(c) We are investigating alternate methods for holding the reservoir solutions,
including gels, beads, sponges and physical barriers.
(3) Since it now appears that solutions may be stable within the glass tips, without
the necessity of a stopper mechanism, we plan to try additional liquid-liquid
diffusion experiments on future flights. We had temporarily abandoned these
experiments, since our current hardware configuration did not permit us to
extrude samples from two syringes while also stoppering these syringe tips.
(4) More attention will be given to photographic procedures, including lighting, film
type and choice of lenses.
(5) Thermal waxes will be used to control the temperature of the samples after they
are removed from the shuttle.
(6) A bracket will be designed to hold the syringe assemblies in the mid-deck area.
This bracket will permit syringes to be activated and deactivated, and
photography to be performed, while keeping the syringe assemblies in a fixed
position.
(7) In the future, syringe tips will be made of precision glass tubing. This should
eliminate the problem that Dr. Musgrave encountered with rotating syringe tips
during drop deployment.
(8) We need to improve the procedures that are used for activating the dialysis
experiments, since the technique that we used on 51-F resulted in ruptured
membranes on three of the dialysis cells. We are now testing alternative
mechanisms for activating these experiments on the shuttle.
